Hyponatraemia-treatment standard 2024.
A 2024 treatment standard for hyponatremia reaffirms rapid intermittent boluses of 3% hypertonic saline for symptomatic cases and fluid restriction first-line for mild asymptomatic disease, while highlighting urea and tolvaptan as the most effective second-line options for SIADH and favoring gradual, monitored correction over rapid normalization.
Background
Hyponatremia is the most common electrolyte disorder in hospitalized patients and is linked to higher morbidity, mortality, longer stays, and cost. This treatment standard consolidates current best practice for its management.
Key recommendations
For symptomatic hyponatremia, rapid intermittent administration of 3% sodium chloride (100–150 mL IV bolus or continuous infusion) is preferred, titrated to symptom severity with frequent biochemical monitoring. For mild asymptomatic hyponatremia, adequate solute (salt and protein) intake plus initial fluid restriction (~500 mL/day, adjusted to serum sodium) is first-line. Because nearly half of SIADH patients do not respond to fluid restriction, urea and tolvaptan are the most effective second-line therapies — though high-quality evidence to guide the choice is lacking; oral urea is highlighted as very effective and safe.
Clinical implications
Treatment is guided by symptom severity and chronicity, not laboratory targets: gradual correction with clinical evaluation is preferred over rapid normalization. Readiness to give hypotonic fluids or desmopressin and close monitoring are crucial to prevent and, if needed, reverse overcorrection.
Category
Transplant
Source
Nephrology Dialysis Transplantation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.